Us Bancorp \De\ Replimune Group, Inc. Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

A detailed history of Us Bancorp \De\ transactions in Replimune Group, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 652 shares of REPL stock, worth $7,993. This represents 0.0% of its overall portfolio holdings.

Number of Shares

652

Previous 781 16.52%

Holding current value

$7,993

Previous $7,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$8.09 - $11.23 $1,043 - $1,448	-129 Reduced 16.52%	652 $7,000
Q2 2024 Aug 06, 2024	BUY	$5.01 - $9.46 $2,459 - $4,644	491 Added 169.31%	781 $7,000
Q1 2024 May 07, 2024	BUY	$6.87 - $9.31 $1,236 - $1,675	180 Added 163.64%	290 $2,000
Q4 2023 Feb 09, 2024	SELL	$6.75 - $16.18 $769 - $1,844	-114 Reduced 50.89%	110 $0
Q3 2023 Nov 03, 2023	SELL	$15.96 - $22.18 $313,661 - $435,903	-19,653 Reduced 98.87%	224 $3,000
Q2 2023 Aug 09, 2023	BUY	$15.65 - $24.1 $27,841 - $42,873	1,779 Added 9.83%	19,877 $461,000
Q1 2023 May 09, 2023	SELL	$17.48 - $29.09 $12,323 - $20,508	-705 Reduced 3.75%	18,098 $319,000
Q4 2022 Feb 13, 2023	BUY	$17.09 - $27.91 $307,449 - $502,100	17,990 Added 2212.79%	18,803 $511,000
Q3 2022 Oct 27, 2022	SELL	$15.6 - $21.15 $2,480 - $3,362	-159 Reduced 16.36%	813 $14,000
Q2 2022 Aug 01, 2022	BUY	$13.32 - $19.98 $12,947 - $19,420	972 New	972 $17,000
Q1 2021 Apr 28, 2021	SELL	$30.22 - $45.57 $7,403 - $11,164	-245 Closed	0 $0
Q4 2020 Feb 04, 2021	BUY	$23.5 - $52.65 $5,757 - $12,899	245 New	245 $9,000

Others Institutions Holding REPL

# of Institutions

149

Shares Held

68M

Call Options Held

52.3K

Put Options Held

80.3K

View Full List

About Replimune Group, Inc.

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $605M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

More about REPL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account